Search

Displaying results 1911 - 1920 of 10000 in total
  1. Drug

    Freneslerbart

    go.drugbank.com/drugs/DB19080
    Investigational

    Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic

    Synonyms: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908, Immunoglobulin G4 [227-proline], anti-(Felis catus allergen Fel d1) (human monoclonal REGN1908 γ4-chain), disulfide with human monoclonal REGN1908 κ-chain, dimer
  2. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. … A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in

  3. Drug

    Trimethoprim

    go.drugbank.com/drugs/DB00440
    ApprovedInvestigationalVet approved

    [L11893] Trimethoprim is often used in combination with [sulfamethoxazole] due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of … Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it

    Mixtures: DBL™ SULFAMETHOXAZOLE AND TRIMETHOPRIM CONCENTRATE INJECTION, DBL SULFAMETHOXAZOLE 400MG AND TRIMETHOPRIM 80MG CONCENTRATE INJECTION BP
  4. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors. … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement

  5. Drug

    AVX-001

    go.drugbank.com/drugs/DB19194
    Investigational

    AVX-001 is under investigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult

  6. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014.

    Synonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
  7. Drug

    Gramicidin D

    go.drugbank.com/drugs/DB00027
    ApprovedInvestigational

    Active against most Gram-positive bacteria and some Gram-negative organisms, Gramicidin D is used primarily as a topical antibiotic and is also found in Polysporin ophthalmic solution. … Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus

    Synonyms: Gramicidin D, Bacillus brevis gramicidin D
  8. Drug

    Curcumin

    go.drugbank.com/drugs/DB11672
    ApprovedInvestigational

    Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in [Curcuma xanthorrhiza oil]. … It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166].

    Mixtures: GelCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Zinc sulfate, unspecified form

    go.drugbank.com/drugs/DB14548
    Approved

    Zinc sulfate is a common zinc supplement in parenteral nutrition.[A216916,L12888]

    Mixtures: Aqua De Folli Hair Booster, Aqua De Folli Hair Booster Pro
  10. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection. … Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to _Clostridium difficile_ toxin B and neutralizes its effects.